Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis
JS Lasa, PA Olivera, S Danese… - The Lancet …, 2022 - thelancet.com
Background There is a growing armamentarium for the treatment of moderate-to-severe
ulcerative colitis. We aimed to compare the relative efficacy and safety of biologics and small …
ulcerative colitis. We aimed to compare the relative efficacy and safety of biologics and small …
ECCO guidelines on therapeutics in ulcerative colitis: medical treatment
Ulcerative colitis [UC] is a chronic inflammatory bowel disease [IBD] characterised by colonic
inflammation extending to a variable extent from the rectum. Care of the patient with UC …
inflammation extending to a variable extent from the rectum. Care of the patient with UC …
STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD …
D Turner, A Ricciuto, A Lewis, F D'amico, J Dhaliwal… - Gastroenterology, 2021 - Elsevier
Background The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE)
initiative of the International Organization for the Study of Inflammatory Bowel Diseases …
initiative of the International Organization for the Study of Inflammatory Bowel Diseases …
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
H Nakase, M Uchino, S Shinzaki, M Matsuura… - Journal of …, 2021 - Springer
Inflammatory bowel disease (IBD) is a general term for chronic or remitting/relapsing
inflammatory diseases of the intestinal tract and generally refers to ulcerative colitis (UC) …
inflammatory diseases of the intestinal tract and generally refers to ulcerative colitis (UC) …
Newer biologic and small-molecule therapies for inflammatory bowel disease
DC Baumgart, C Le Berre - New England Journal of Medicine, 2021 - Mass Medical Soc
Newer Biologic and Small-Molecule Therapies for IBD There is still no cure for inflammatory
bowel disease. This review covers newer treatments that reflect our understanding of the …
bowel disease. This review covers newer treatments that reflect our understanding of the …
Crohn's disease
G Roda, S Chien Ng, PG Kotze, M Argollo… - Nature Reviews …, 2020 - nature.com
Crohn's disease is an inflammatory bowel disease that is characterized by chronic
inflammation of any part of the gastrointestinal tract, has a progressive and destructive …
inflammation of any part of the gastrointestinal tract, has a progressive and destructive …
[HTML][HTML] Ulcerative colitis—diagnostic and therapeutic algorithms
T Kucharzik, S Koletzko, K Kannengiesser… - Deutsches Ärzteblatt …, 2020 - ncbi.nlm.nih.gov
Background Ulcerative colitis is a chronic inflammatory bowel disease with an estimated 150
000 patients in Germany alone. Methods This review is based on publications about current …
000 patients in Germany alone. Methods This review is based on publications about current …
First-and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis
Background & Aims We compared the efficacy and safety of different first-line (biologic-
naïve) and second-line (prior exposure to tumor necrosis factor [TNF] antagonists) agents for …
naïve) and second-line (prior exposure to tumor necrosis factor [TNF] antagonists) agents for …
Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy
P Pavlidis, A Tsakmaki, E Pantazi, K Li… - Nature …, 2022 - nature.com
The function of interleukin-22 (IL-22) in intestinal barrier homeostasis remains controversial.
Here, we map the transcriptional landscape regulated by IL-22 in human colonic epithelial …
Here, we map the transcriptional landscape regulated by IL-22 in human colonic epithelial …